The author, after reviewing the data, agrees with ICN.
Ribavirin is active against respiratory syncytial
virus (
RSV), a
common infection in children. It is approved by the FDA for this
use in the U.S., but the approved preparation is a liquid
preparation for aerosol delivery. Though some of the drug is
absorbed orally when used in this fashion, no oral preparation
has been approved in the U.S. Use of the pediatric formulation
in adults for other purposes would be prohibitively expensive.